2. Apoptosis
  3. Thymidylate Synthase
  4. Fosifloxuridine nafalbenamide

Fosifloxuridine nafalbenamide  (Synonyms: NUC-3373)

目录号: HY-109115 纯度: 96.05%
COA 产品使用指南

摩尔计算器

Fosifloxuridine nafalbenamide (NUC-3373) 属于嘧啶核苷酸类似物，是一种胸腺嘧啶合酶 (Thymidylate synthase) 抑制剂。Fosifloxuridine nafalbenamide 具有抗癌活性。Fosifloxuridine nafalbenamide 具有诱发宿主免疫反应和增强免疫研究的潜力。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

我们将采用定制合成服务的方式为您快速提供所需产品和技术服务

Fosifloxuridine nafalbenamide Chemical Structure

Fosifloxuridine nafalbenamide Chemical Structure

CAS No. : 1332837-31-6

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ￥2700
In-stock
1 mg ￥1000
In-stock
5 mg ￥2000
In-stock
10 mg ￥2800
In-stock
25 mg ￥5000
In-stock
50 mg 现货 询价
100 mg 现货 询价
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Customer Review

Fosifloxuridine nafalbenamide 相关抗体

Top Publications Citing Use of Products

MCE 顾客使用本产品发表的 1 篇科研文献

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

Fosifloxuridine nafalbenamide (NUC-3373), a pyrimidine nucleotide analogue, is a Thymidylate synthase inhibitor. Fosifloxuridine nafalbenamide has anticancer activity. Fosifloxuridine nafalbenamide has the potential to evoke a host immune response and enhance immunoresearch[1][2].

细胞效力
(Cellular Effect)
Cell Line Type Value Description References
CCRF-CEM IC50
0.05 μM
Compound: 7m, diastereomeric mixture
Cytostatic activity against human CEM cells expressing human ENT1 transporter after 72 hrs by cell counting
Cytostatic activity against human CEM cells expressing human ENT1 transporter after 72 hrs by cell counting
[PMID: 21892829]
CCRF-CEM IC50
0.068 μM
Compound: 7m, diastereomeric mixture
Cytostatic activity against human CEM/0 cells after 72 hrs by cell counting
Cytostatic activity against human CEM/0 cells after 72 hrs by cell counting
[PMID: 21892829]
CCRF-CEM IC50
0.13 μM
Compound: 7m, diastereomeric mixture
Cytostatic activity against human CEM cells expressing human ENT1 transporter after 72 hrs by cell counting in presence of dipyridamole
Cytostatic activity against human CEM cells expressing human ENT1 transporter after 72 hrs by cell counting in presence of dipyridamole
[PMID: 21892829]
CCRF-CEM IC50
0.26 μM
Compound: 7m, diastereomeric mixture
Cytostatic activity against human CEM cells expressing human ENT1 transporter after 72 hrs by cell counting in presence of NBMPR
Cytostatic activity against human CEM cells expressing human ENT1 transporter after 72 hrs by cell counting in presence of NBMPR
[PMID: 21892829]
CCRF-CEM IC50
0.31 μM
Compound: 7m, diastereomeric mixture
Cytostatic activity against thymidine-kinase deficient human CEM cells after 72 hrs by cell counting
Cytostatic activity against thymidine-kinase deficient human CEM cells after 72 hrs by cell counting
[PMID: 21892829]
CCRF-CEM IC50
0.6 μM
Compound: 7m, diastereomeric mixture
Cytostatic activity against ENT1 transporter-deficient human CEM cells after 72 hrs by cell counting
Cytostatic activity against ENT1 transporter-deficient human CEM cells after 72 hrs by cell counting
[PMID: 21892829]
HeLa IC50
0.065 μM
Compound: 7m, diastereomeric mixture
Cytostatic activity against human HeLa cells after 72 hrs by cell counting
Cytostatic activity against human HeLa cells after 72 hrs by cell counting
[PMID: 21892829]
HeLa IC50
2.5 μM
Compound: 7m, diastereomeric mixture
Cytostatic activity against thymidine-kinase deficient human HeLa cells after 72 hrs by cell counting
Cytostatic activity against thymidine-kinase deficient human HeLa cells after 72 hrs by cell counting
[PMID: 21892829]
L1210 IC50
0.025 μM
Compound: 7m, diastereomeric mixture
Cytostatic activity against Mycoplasma hyorhinis-infected mouse L1210 cells after 48 hrs by cell counting
Cytostatic activity against Mycoplasma hyorhinis-infected mouse L1210 cells after 48 hrs by cell counting
[PMID: 21892829]
L1210 IC50
0.045 μM
Compound: 7m, diastereomeric mixture
Cytostatic activity against thymidine-kinase deficient mouse L1210 cells after 48 hrs by cell counting
Cytostatic activity against thymidine-kinase deficient mouse L1210 cells after 48 hrs by cell counting
[PMID: 21892829]
体外研究
(In Vitro)

Fosifloxuridine nafalbenamide induces the release of damage-associated molecular patterns (DAMPs), with increased expression of calreticulin (CRT) at the cell surface and concomitant loss of nuclear nuclear high mobility group box protein 1 (HMGB1)[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Fosifloxuridine nafalbenamide 相关抗体:
体内研究
(In Vivo)

Fosifloxuridine nafalbenamide exhibits anti-cancer activity in HT-29 nude mouse xenograft models[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
分子量

613.53

Formula

C29H29FN3O9P
CAS 号
性状

固体

颜色

White to off-white

运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
溶解性数据
细胞实验： 

DMSO 中的溶解度 : 100 mg/mL (162.99 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.6299 mL 8.1496 mL 16.2991 mL
5 mM 0.3260 mL 1.6299 mL 3.2598 mL
查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C储存时，请在2年内使用， -20°C储存时，请在1年内使用。

  • 摩尔计算器

  • 稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量
=
浓度
×
体积
×
分子量 *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start)

C1

×
体积 (start)

V1

=
浓度 (final)

C2

×
体积 (final)

V2

动物实验：

请根据您的 实验动物和给药方式 选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 方案 一

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (4.07 mM); 澄清溶液

    此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水 定容至 1 mL。

    生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
  • 方案 二

    请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (4.07 mM); 澄清溶液

    此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液 中，混合均匀。

    2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。
动物溶解方案计算器
请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

g

每只动物的给药体积

μL

动物数量

只
由于实验过程有损耗，建议您多配一只动物的量
请输入您的动物体内配方组成：
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。
方案所需 助溶剂 包括：DMSO， ，均可在 MCE 网站选购。 ，Tween 80，均可在 MCE 网站选购。
计算结果
工作液所需浓度 : mg/mL
储备液配制方法 : mg 药物溶于 μL  DMSO（母液浓度为 mg/mL）。
您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。
动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。
连续给药周期超过半月以上，请谨慎选择该方案。
请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热 （超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。
纯度 & 产品资料
参考文献

Fosifloxuridine nafalbenamide 相关分类

完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C储存时，请在2年内使用， -20°C储存时，请在1年内使用。

可选溶剂 浓度 溶剂体积 质量 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 1.6299 mL 8.1496 mL 16.2991 mL 40.7478 mL
5 mM 0.3260 mL 1.6299 mL 3.2598 mL 8.1496 mL
10 mM 0.1630 mL 0.8150 mL 1.6299 mL 4.0748 mL
15 mM 0.1087 mL 0.5433 mL 1.0866 mL 2.7165 mL
20 mM 0.0815 mL 0.4075 mL 0.8150 mL 2.0374 mL
25 mM 0.0652 mL 0.3260 mL 0.6520 mL 1.6299 mL
30 mM 0.0543 mL 0.2717 mL 0.5433 mL 1.3583 mL
40 mM 0.0407 mL 0.2037 mL 0.4075 mL 1.0187 mL
50 mM 0.0326 mL 0.1630 mL 0.3260 mL 0.8150 mL
60 mM 0.0272 mL 0.1358 mL 0.2717 mL 0.6791 mL
80 mM 0.0204 mL 0.1019 mL 0.2037 mL 0.5093 mL
100 mM 0.0163 mL 0.0815 mL 0.1630 mL 0.4075 mL
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Fosifloxuridine nafalbenamide1332837-31-6NUC-3373NUC3373NUC 3373Thymidylate SynthasefluorodeoxyuridinemonophosphateFdUMP5-fluorouracil5-FU5-fluorodeoxyuridineFUDRanti-cancerInhibitorinhibitorinhibit

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称：

  

* 需求量：

* 客户姓名：

 

* Email：

* 电话：

 

* 公司或机构名称：

   留言给我们：

Bulk Inquiry

Inquiry Information

产品名称：
Fosifloxuridine nafalbenamide
目录号：
HY-109115
需求量：

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

   产品名称：

  

* Lot #：

* 客户姓名：

 

* Email：

   电话：

 

* 部门：

* 公司或机构名称：

 

   留言给我们：

Request for HNMR Report

We have received your request and will respond to you as soon as possible.

嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z